The U.S. Department of Health and Human Services calls it “the next evolution in medical treatments” and says, “This revolutionary technology has the potential to develop therapies for previously untreatable diseases and conditions.”
“It offers a ‘disruptive innovation’ strategy uniquely poised to add value and transform health care,” reports The Journal of the American College of Cardiology And The Wall Street Journal says some early investors “are set to make spectacular returns.”
The cause of this buzz?
“Regenerative Medicine” – therevolutionary technology that can “rebuild” damaged human organs. I’m talking about the possibility of replacing an injured factory worker’s hand… an accident victim’s spleen… even a deaf woman’s eardrums.
Furthermore, research shows it has the potential to not just treat – but actually cure – no less than eight of the world’s most deadly diseases, including cancer, heart disease and diabetes.
And for investors? This groundbreaking development could trigger a cash explosion projected at almost $500 billion.
So how do you turn that into huge short-term gains?
How to Play Regenerative Medicine for Potential 500% Gains:
We’re still in the early stages of understanding the power of regenerative cells. But already, one company has seen remarkable success in this field.
Their lead product facilitates breast reconstruction following a partial mastectomy.
More than 600,000 women worldwide are diagnosed with breast cancer every year… and over 75% (some 450,000 cases) are eligible for reconstruction. Obviously, this presents a huge potential market for this company’s non-invasive product.
This company hasn’t yet begun marketing efforts in North America.
But thanks to approvals in Europe and Asia, scientists and doctors around the world are already testing the technology.
Scientists recently evaluated difficult-to-treat breast reconstruction patients six months after a single treatment.
Over 70% of patients and more than 80% of doctors expressed satisfaction with the outcome.
And its breast reconstruction process is just the beginning.
Doctors are also now testing these innovations for burn reconstruction, treating liver problems, tendon injury, periodontal disease, stroke, heart attack, acute kidney injury and more.
And because we’re still very early in this technology cycle, any clinical advances will be met with great enthusiasm… by doctors, patients… and shareholders.
Right now this company is still small. With a market cap around $110 million, its shares trade at around $3 as we speak.
Yet estimates show the regenerative medicine market is poised to mushroom to $30 billion annually.
Even if this company captures just 3% of the market, that could mean $900 million in new annual revenue.
Apply a conservative price-to-earnings ratio of 14, and that puts the price of this little $3 stock at more than $18 ($18.20) a share. That’s a 500%-plus gain.
I’ll show you how to receive the exact ticker symbol for this company in just a moment.
But first, I’ve identified another major opportunity I want to let you know about…